AmbioPharm, a worldwide leader in peptide active pharmaceutical ingredient (API) contract development and manufacturing organization (CDMO) services, announced the appointment of industry veteran Brian Gregg as Chief Executive Officer, today. Mr. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after 7 years with the company.
Mr. Gregg joins AmbioPharm following a 32-year career at Bachem Americas, where he was Chief Operating Officer for nearly a decade and was responsible for driving business and operational growth with the strategic acquisition and integration of a competing peptide CDMO. During his earlier years at Bachem, Mr. Gregg led the quality and regulatory function for Bachem Americas before serving as site manager for Bachem’s GMP manufacturing location in Torrance, California. Mr. Gregg will play a pivotal role in expanding AmbioPharm’s leadership role in the fast-growing peptide CDMO market and growing the company’s global customer base.
Dr. Juncai (Chris) Bai, Chairman of the Company, said, “We are excited to welcome Brian to our executive team. He has both the leadership experience and necessary background to be immediately effective in growing our business in the U.S. and globally, and we look forward to working with him as we continue to expand on our service offerings and global customer base.”
Ms. Ling Yang, Managing Director of Carlyle and member of the Board, commented, “The industry sector continues to demonstrate significant growth, driven by end-market innovation globally, and we believe Brian has a demonstrated and proven industry track record to lead AmbioPharm in its next phase of growth. Carlyle has worked with AmbioPharm since our investment in 2018 to help transform the company and build out its operational capabilities, and we continue to provide unwavering support to the company as it seeks to expand its leading position in the CDMO market.”
Mr. Gregg said, “AmbioPharm has invested significant effort and capital building out its systems, organization, buildings, and equipment, and the company is well-positioned to capture the opportunities in the global peptide CDMO market. It is an exciting time to take the reins of the company and I look forward to working with the leadership team to capitalize on these opportunities as well as to deliver high-quality products and service excellence for AmbioPharm’s customers.”
Mr. Gregg holds an MBA from the San Diego State University and a Bachelor of Arts degree in Chemistry from the University of California at San Diego.
About AmbioPharm
AmbioPharm, a global peptide CDMO, was founded in 2005 and is headquartered in North Augusta, South Carolina, USA, specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at small to very large scales. Its manufacturing facilities in South Carolina, USA and Shanghai, China, manufacture New Chemical Entities (NCEs) and generic peptide APIs under cGMP for clients worldwide. The company currently has over 600 employees in North America, Asia and Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231002156576/en/
Contacts
Stephen Kiel, Secretary/Treasurer and CFO (803) 442-7590
